Urolog. pro Praxi, 2006; 4: 168-170

Medikamentózna a chirurgická liečba benígnej hyperplázie prostaty v Slovenskej republike -

doc. MUDr. Ján Švihra PhD1, MUDr. Tibor Baška PhD1, MUDr. Angelika Szalayová2, Donald M. Bushnell MA3, MUDr. Ladislav Macko4, MUDr. Ladislav Poliak5, doc. MUDr. Ján Ľupták PhD5, prof. MUDr. Ján Kliment CSc5
1 Ústav epidemiológie JLF UK Martin
2 Ústav farmakológie LF UK Bratislava
3 Health Research Associates, Seattle, USA
4 Urologická ambulancia, Levice
5 Urologická klinika JLF UK, Martin

Cieľ: Porovnať účinok liekov na potrebu chirurgickej liečby benígnej hyperplázie prostaty (BPH) u slovenských mužov počas sledovania 10 rokov.

Klinický súbor a metódy: Register ministerstva zdravotníctva Slovenskej republiky bol použitý na identifikáciu pacientov s BPH. Všetci pacienti boli zaradení v rozsahu rokov 1995 až 2004. Vstupné Critéria boli stredné a závažné symptómy dolných močových ciest pre benígnu prostatickú obštrukciu, znížený prietok moču pod 15 ml/s a zväčšená prostate pri digitálnom rektálnom vyšetrení. Pacienti s karcinómom prostaty alebo močového mechúra boli vylúčení. Primárny cieľ štúdie bol identifikovať zmeny v medikamentóznej liečbe BPH, sekundárny cieľ bol identifikovať zmeny v chirurgickej liečbe BPH.

Výsledky: Celkove bolo vyhodnotených 600 tisíc údajov. Vstupná charakteristika bola identická v oboch sledovaných skupinách. Priemerná medikamentózna liečba BPH bola 3,7 vs. 2,6 vs. 3,5 mesiacov u alfa-blokátorov vs finasteridu vs. fytoterapii. Podľa Slovenského registra bola väčšina pacientov liečená alfa-blokátormi (74,5 % – medikamentózna liečba) a TURP (73,0 % – chirurgická liečba). Použitie medikamentóznej liečby BPH narástlo v rokoch 1995 až 2004 o 496,0 % (od 30,5 do 181,8/1 000 mužov). Chirurgická liečba BPH sa v rokoch 1995 až 2004 znížila o 19,4 % pre TURP (od 3,1 do 2,5/1,000 mužov) a 53,3% pre prostatektómiu (od 1,5 do 0,7/1 000 mužov). Krivky incidencie chirurgickej a medikamentóznej liečby BPH boli štatisticky signifikantne divergentné (p 

Keywords: Kľúčové slová: prostata, prostatektómia, alfa-blokátory, finasterid, fytoterapia.

Published: January 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Švihra J, Baška T, Szalayová A, Bushnell DM, Macko L, Poliak L, et al.. Medikamentózna a chirurgická liečba benígnej hyperplázie prostaty v Slovenskej republike -. Urol. praxi. 2006;7(4):168-170.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. AUA BPH Guideline Update Panel. The Management of BPH, 2003.<http://www.auanet.org/ timssnet/products/guidelines/bph_management.cfm>.
    2. Barry MJ, Fowler FJ Jr, O'Leary MP et al. Measuring disease-specific health status in men with benign prostatic hyperplasia. Measurement Committee of the American Urological Association. Med Care 1995; 33: 145.
    3. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984; 132: 474. Go to original source... Go to PubMed...
    4. Breza J. Metodický list racionálnej farmakoterapie 18. Benígna hyperplázia prostaty. Metodický list Ústrednej komisie racionálnej farmakoterapie a liekovej politiky MZ SR. Herba Bratislava 2001; 5: 1-4.
    5. de la Rosette JJ, Alivizatos G, Madersbacher S et al. for the European Association of Urology. EAU Guidelines on benign prostatic hyperplasia (BPH). Eur Urol 2001; 40: 256-263. Go to original source... Go to PubMed...
    6. Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hypertrophy in the community. Lancet 1991; 338: 469-471. Go to original source... Go to PubMed...
    7. Garraway WM, Russell EB, Lee RJ et al. Impact of previously unrecognized benign prostatic hyperplasia on the daily activities of middle-aged and elderly men. Br J Gen Pract 1993; 43: 318.
    8. Girman CJ, Jacobsen SJ, Tsukamoto T et al. Health-related quality of life associated with lower urinary tract symptoms in four countries. Urol 1998; 51: 428-436. Go to original source... Go to PubMed...
    9. Horňák M, Breza J, Bárdoš G Jr. Benígna prostatická hyperplázia: postavenie klasických operačných postupov na Slovensku. Urol 2000; 6: 31-33.
    10. Chatelain C, Denis L, Foo KT et al. Proceedings of the fifth international consultation on benign prostatic hyperplasia. Edited by United Kingdom: Health Publications Ltd. 2001; 3: 79-106.
    11. Kliment J, Horňák M, Beseda A, Švihra J. Benígna hyperplázia prostaty. Hálkova zbierka. Martin: Osveta 1996: 142-181.
    12. Madersbacher S, Lackner J, Brossner C et al. For the prostate study group of the austrian society of urology. Reoperation, myocardial infarction and mortality after transurethral and open prostatectomy: A nation-wide, long-term analysis of 23,123 cases. Eur Urol 2005; 47: 499-504. Go to original source... Go to PubMed...
    13. Roberts RO, Rhodes T, Panser LA et al. Natural history of prostatism: worry and embarrassment from urinary symptoms and health care-seeking behavior. Urology 1994; 43: 621. Go to original source... Go to PubMed...
    14. Roehrborn CG, McConnell JD. Etiology, pathophysiology, epidemiology and natural history of benign prostatic hyperplasia. In Campbell's Urology. Walsh PC, Retik AB, Vaughan, ED Jr and Wein AJ. Philadelphia, PA: W. B. Saunders Company 2002; 38: 1297-1330.
    15. Souverein PC, Erkens JA, de la Rosette JJMCH et al. Drug treatment of benign prostatic hyperplasia and hospital admission for BPH-related surgery. Eur Urol 2003; 43: 528-534. Go to original source... Go to PubMed...
    16. Souverein PC, van Riemsdijk MM, de la Rosette JJMCH et al. Treatment of benign prostatic hyperplasia and occurrence of prostatic surgery and acute urinary retention: A population-based cohort study in the Netherlands. Eur Urol 2005; 47: 505-510. Go to original source... Go to PubMed...
    17. Šafařík L, Povýšil C. Benigní hyperplazie prostaty. In: Dvořáček J et al. Urologie. Praha: ISV 1998: 1197-1252.
    18. Švihra J. Urodynamické vyšetrenia pri benígnej hyperplázii prostaty. Martin: JLF UK 1998: 135.
    19. Švihra J, Eliáš B, Javorka K Jr, Kliment J. Prevalencia benígnej hyperplázie prostaty a symptómov dolných močových ciest. Slov Radiol 2000; 7: 35-38.
    20. Tubaro A. BPH Treatment: A Paradigm Shift. Eur Urol 2006; 49: 939-941. Go to original source... Go to PubMed...
    21. van Exel NJA, Koopmanschap MA, McDonnell J et al. TRIUMPH Pan-European expert panel. Medical consumption and costs during a one-year follow-up of patients with LUTS suggestive of BPH in six European countries: Report of the TRIUMPH Study. Eur Urol 2006; 49: 92-102. Go to original source... Go to PubMed...
    22. Verhamme KMC, Dieleman JP, Bleumink GS et al. Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care - The Triumph project. Eur urol 2002; 42: 323-328. Go to original source... Go to PubMed...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.